Eli Lilly has filed six lawsuits against companies accused of selling illegal, unapproved versions of its experimental obesity drug, retatrutide. The targeted businesses include medical spas, compounding pharmacies, and various online retailers. While retatrutide remains in clinical development and has not received regulatory approval for human use, demand for weight-loss medications has created a dangerous black market for the product.
Dr. David Hyman, chief medical officer at Lilly, warned that products sold through these unauthorized channels are unverified and pose significant health risks to consumers. The company is actively working to identify and stop these illicit sellers who market drugs sourced from unregulated manufacturers. Lilly has already referred over 200 entities to federal authorities, including the FDA and the Department of Justice.
The scale of this issue is growing, with U.S. Customs and Border Protection reporting that the seizure of illicit GLP-1 drugs has surged in recent months. Nearly 90,000 vials were intercepted in July alone. In response, Lilly is pressuring e-commerce platforms, payment processors, and shipping companies to cut off these illegal sellers and prevent further distribution of potentially unsafe substances.
The lawsuits name Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. This legal action marks a firm attempt to curb the distribution of unverified medical products before they cause widespread harm to patients who may believe these black-market items are legitimate treatments.